Or Akiva, Israel, Oct.3, 2013.– On Wednesday, October 2, the clinical effectiveness research results associated with the ActiveCare® were featured in the prestigious Charnley Lecture at the British Orthopaedic Association Congress (BOA) in Birmingham, England. Dr. Robert Barrack, Chief of Orthopedics at Barnes Jewish Hospital (BJC), St. Louis, Missouri, USA presented the Charnley Lecture titled “The History of Thromboprophylaxis in Hip and Knee Replacement Surgery”.
“DVT prevention has been historically an area of global concern amongst orthopedic surgeons as pharmacologic DVT prevention is often associated with a higher rate of bleeding complications in hip and knee replacement patients recovering from surgery”, commented Rick Randall, MCS CEO.
Dr. Barrack informed the surgeons attending the Congress that US DVT prevention guidelines have been modified due to the ActiveCare® clinical results which demonstrated effective DVT prevention and dramatically reduced bleeding complications without the use of anticoagulation medications in hip and knee replacement patients.
ActiveCare® is a comprehensive alternative to anticoagulants during and after hip and knee replacement surgery. It was clinically studied head to head with anticoagulants and was proven to be non inferior in DVT/PE prevention.
The 9th edition of American College of Chest Physicians (ACCP) guidelines published in 2012 recognizes the danger of bleeding and drainage complications resulting from aggressive DVT prophylaxis, which are major problems to the orthopedic surgeons.
In addition to the ACCP 2012 recommendation to use ActiveCare® as standalone therapy without the need for drugs for DVT/PE prevention after total joint arthroplasty for the whole duration of treatment from hospital to home, ActiveCare® is currently used in more than 70 surgical centers across the country daily.
About Medical Compression Systems: Medical Compression Systems (MCS), a developer and manufacturer of ActiveCare® products, is a leader in innovative, non-invasive solutions for the prevention of venous thromboembolism (VTE). The company is the first and currently the only company to offer the healthcare market a new class of proven therapy, which can minimize the need for pharmaceutical therapy as the current standard of care. Founded in 1997, MCS Medical Compression Systems (Ltd.), is an Israeli public company, traded on the Tel Aviv Stock Exchange (TASE: MDCL). MCS Inc., the company’s subsidiary, is located in the USA.
For more info: http://activecare.mcsmed.com/juggling.html
Ms. Tlalit Bussi Tel-Tzure, VP Sales & Marketing